Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

R Star 001

Next Previous
Drug Profile

R Star 001

Alternative Names: R-Star-001

Latest Information Update: 06 Aug 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Shenzhen Celconta Life Science
  • Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Clinical Phase Unknown Solid tumours

Most Recent Events

  • 01 Aug 2025 Shenzhen Celconta Life Science plans a phase I trial for Solid tumours (Late-stae diseases, Second-line therapy or greater) in China (Parentral, Injection) in August 2025 (NCT07101549)
  • 22 Apr 2025 Clinical trials in Solid tumours (Parenteral) prior to April 2025 (Shenzhen Celconta Life Science pipeline, April 2025)
  • 31 Jul 2023 CAR T cell therapy - Synkangda Life is available for licensing as of 31 Jul 2023. https://www-xkdbio-com.translate.goog/yjxm?_x_tr_sl=zh-CN&_x_tr_tl=en&_x_tr_hl=en&_x_tr_pto=sc&_x_tr_sch=http#31

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top